MBMadan Lal Brahma Bhatt

Madan Lal Brahma Bhatt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Madan Lal Brahma Bhatt has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Radiotherapy in cervical cancer

    by Shraddha Srivastava, Nara Singh Moirangthem, Arunima Ghosh, Indrajeet Gupta, Madan Lal Brahma Bhatt

    Radiotherapy plays a significant role in the management of cervix cancer. In recent decades, there have been several advancements in radiation therapy treatment techniques. Moving from conventional two-dimensional techniques to advanced techniques like 3D conformal radiation therapy (3D-CRT), intensity-modulated radiation therapy (IMRT), and volumetric modulated radiation therapy (VMAT) has led to improvement in the treatment outcomes. The aim of radiation therapy is achieved by these advanced techniques, which deliver optimal tumoricidal doses to tumor volumes and minimal doses to the normal tissues around the tumor and can reduce toxicity more effectively than the conventional techniques. These external beam radiotherapy (EBRT) techniques along with brachytherapy play a significant role in the treatment of gynaecological cancer. Compared to point-based dose brachytherapy planning, better local control and lower toxicity have been associated with advanced image-based brachytherapy.


  • Open Access

    The 50-Year Journey of Lung Cancer Screening: A Narrative Review

    by Aneri Parekh, Kunal Deokar, Mrinalini Verma, Sanjay Singhal, Madan Lal Bhatt, Cds Katoch

    Early diagnosis and treatment are associated with better outcomes in oncology. We reviewed the existing literature using the search terms “low dose computed tomography” and “lung cancer screening” for systematic reviews, metanalyses, and randomized as well as non-randomized clinical trials in PubMed from January 1, 1963 to April 30, 2022. The studies were heterogeneous and included people with different age groups, smoking histories, and other specific risk scores for lung cancer screening. Based on the available evidence, almost all the guidelines recommend screening for lung cancer by annual low dose CT (LDCT) in populations over 50 to 55 years of age, who are either current smokers or have left smoking less than 15 years back with more than 20 to 30 pack-years of smoking. “LDCT screening” can reduce lung cancer mortality if carried out judiciously in countries with adequate resources and infrastructure.


  • Palliative radiotherapy: a one-week course in advanced head and neck cancer – quality of life outcomes

    by Sadanand Prakash, Deep Chakrabarti, Rajendra Kumar, Manas Mani Agrawal, Mrinalini Verma, Sudhir Singh, Seema Gupta, Kirti Srivastava, Rajeev Gupta, Madan Lal Brahma Bhatt

    Objectives Palliative radiotherapy regimens for advanced head and neck cancers vary in doses and treatment times. Their quality of life (QoL) implications are not clearly established. Methods We randomised patients with advanced, non-metastatic, head and neck squamous cell carcinomas (stage IVA-B) with WHO performance score of 2 or higher to receive 30 Gy in 10 fractions over two weeks (arm A) or 20 Gy in 5 fractions over one week (arm B). QoL was assessed using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaires (QLQ)-C30 and QLQ-H&N35 questionnaires at baseline and postradiotherapy. The primary endpoint was the EORTC-defined global health status. Secondary endpoints were functional and symptom scores of QoL, response to radiotherapy and acute toxicities. The primary aim was to evaluate the one-week regimen in terms of QoL to the longer regimen. Results 110 patients were randomised, the number of patients in the final analysis was 95: 49 in arm A and 46 in arm B. Baseline characteristics were similar. Clinical outcomes post-treatment were comparable. Postradiotherapy, there were improved scores for functional and symptom scales, the differences were non-significant. The duration of treatment was significantly reduced in arm B (pConclusion One-week palliative radiotherapy for head and neck cancers achieves similar QoL and clinical outcomes as more protracted radiotherapy schedules with significantly reduced treatment time and financial toxicity.


  • Single Nucleotide Polymorphism of MSH3 Gene Alters Head and Neck Squamous-Cell Carcinoma Risk in North-India

    by Suresh Kumar Yadav, Shalini Gupta, Madan Lal Brahma Bhatt, Durga Prasad Mishra, Dayalanand Roy, Somali Sanyal

    Single Nucleotide Polymorphism of MSH3 Gene Alters Head and Neck Squamous-Cell Carcinoma Risk in North-India


  • Open Access

    Expression of Radioresistant Gene PEG10 in OSCC Patients and Its Prognostic Significance

    by Shankar Sharan Singh, Rajendra Kumar, Vandana Singh Kushwaha, Madan Lal Brahma Bhatt, Anshuman Singh, Anupam Mishra, Hari Ram, Devendra Parmar, Rajeev Gupta


  • Open Access

    Role of matrix metalloproteinase 13 gene expression in the evaluation of radiation response in oral squamous cell carcinoma

    by Madan Lal Brahma Bhatt, Shankar Sharan Singh, Vandana Singh Kushwaha, Anshuman Singh, Rajendra Kumar, Rajeev Gupta, Devendra Parmar

    BACKGROUND: Matrix Metalloproteinase 13 (MMP13) is a member of collagenase family and it is involved in the degradation of extracellular matrix and basement membrane protein. It is thought to be associated with tumor invasion and metastasis. Elevated MMP13 expression has been found in carcinoma of the breast, urinary bladder, head and neck and others. It is observed that MMP13 gene is also correlated with radiation response in OSCC (Oral squamous cell carcinoma) cell line based study. The present study correlates the MMP13 expressions with clinicopathological parameters and radiation response in OSCC patients. MATERIALS AND METHODS: The MMP13 mRNA levels were determined by employing qRT-PCR (real-time quantitative reverse transcriptase-polymerase chain reaction). RESULTS: We observed high expression of MMP13 mRNA in OSCC patients when compared with matched controls. Statistically significant up regulation of MMP13 mRNA expression was found in tobacco chewers, advanced T-stage (p < 0.001) and lymph node metastasis (p < 0.01). MMP13 mRNA levels were also elevated in non responders as compared to responders to radiation treatment. CONCLUSIONS: To the best of our knowledge, this is the first report that indicates role of MMP13 in radiation response in OSCC patients and could be used as potential bio-marker for radiotherapy treatment in OSCC patients.


  • Open Access

    Evaluation of KiSS1 as a Prognostic Biomarker in North Indian Breast Cancer Cases

    by Richa Singh, Madan Lal Brahma Bhatt, Saurabh Pratap Singh, Vijay Kumar, Madhu Mati Goel, Durga Prasad Mishra, Rajendra Kumar

    Breast cancer is the commonest female cancer worldwide and its propensity to metastasize negatively impacts on therapeutic outcome. Several clinicopathological parameters with prognostic/predictive significance have been associated with metastatic suppressor expression levels. The role of metastatic suppressor gene (MSG) KiSS1 in breast cancer remains unclear. Our goal was to investigate the possible clinical significance of KiSS1 breast cancer. The study was conducted on 87 histologically proven cases of breast cancer and background normal tiisue. Quantitative reverse transcriptase polymerase chain reaction (qRT PCR) and immunohistochemistry (IHC) were used to investigate KiSS1 at gene and protein levels, respectively, for correlation with several patient characteristics including age, family history, hormonal receptor status, stage, tumor size, nodal involvement and metastatic manifestation and finally with median overall survival (OS). Our study revealed (i) KiSS1 levels were generally elevated in breast cancer vs normal tissue (< 0.05). (ii) however, a statistically significant lower expression of KiSS1 was observed in metastatic vs non metastatic cases (P = 0.04). (iii) KiSS1 levels strongly correlated with T,N,M category, histological grade and advanced stage (<0.001) but not other studied parameters. (iv) Lastly, a significant correlation between expression of KiSS1 and median OS was found (P = 0.04). Conclusively, less elevated KiSS1 expression is a negative prognostic factor for OS, advancing tumor stage, axillary lymph node status, metastatic propensity and advancing grade of the breast cancer patient. Patients with negative KiSS1 expression may require a more intensive therapeutic strategy.


    • 1 January 2016
      • Vol. 17  (7) , 3431-6

    Expression Levels of Tetraspanin KAI1/CD82 in Breast Cancers in North Indian Females.

    by Richa Singh, Madan Lal Brahma Bhatt, Saurabh Pratap Singh, Vijay Kumar, Madhu Mati Goel, Durga Prasad Mishra, Kirti Srivastava, Rajendra Kumar

    Carcinogenesis is a multifaceted intricate cellular mechanism of transformation of the normal functions of a cell into neoplastic alterations. Metastasis may result in failure of conventional treatment and death Hence, research on metastatic suppressors in cancer is a high priority. The metastatic suppressor gene CD82, also known as KAI1, is a member of the transmembrane 4 superfamily which was first identified in carcinoma of prostate. Little work has been done on this gene in breast cancer. Herein, we aimed to determine the gene and protein level expression of CD82/KAI1 in breast cancer and its role as a prognosticator. In this study, 83 histologically proven cases of breast cancer and a similar number of controls were included. Patient age ranged from 1870 years. Quantitative Real Time Polymerase Chain Reaction (qRT PCR) and immunohistochemistry (IHC) were used to investigate KAI1 expression at gene and protein levels, respectively. Statistical analysis was done to correlate expression of KAI1 and clinicopathological parameters. It was revealed that: (i) KAI1 was remarkably diminished in metastatic vs non metastatic breast cancer both at the gene and the protein levels (P<.05); (ii) KAI1 expression levels were strongly correlated with TNM staging, histological grade and advanced stage (p<0.001) and no association was found with any other studied parameter; (iii) Lastly, a significant correlation was observed between expression of KAI1 and overall median survival of BC patients (P = 0.04). Our results suggest that lack of expression of the KAI1 might indicate a more aggressive form of breast cancer. Loss of KAI1 may be considered a significant prognostic marker in predicting metastatic manifestation. When evaluated along with the clinical and pathological factors, KAI1 expression may be beneficial to tailor aggressive therapeutic strategies for such patients.


  • Appraisal of diagnostic ability of UCA1 as a biomarker of carcinoma of the urinary bladder

    by A. K. Srivastava, P. K. Singh, S. K. Rath, D. Dalela, M. M. Goel, M. L. B. Bhatt

    Initial diagnosis of carcinoma of the urinary bladder remains to be a challenge. Urine cytology, as an adjunct to cystoscopy, is less sensitive for low-grade tumors. Urothelial cancer associated 1 (UCA1) is a novel non-coding RNA gene, which plays a pivotal role in bladder cancer progression. Our aim is to investigate the significance of urinary UCA1 for the non-invasive diagnosis of transitional cell carcinoma (TCC) of the urinary bladder. We examined UCA1 expression in a bladder cancer cell line (T24) and in urine of 28 healthy individuals, 46 patients of non-malignant disorders, and 117 cases (69 primary and 48 recurrent cases) of histologically proven TCC prior to transurethral resection by using real-time PCR and compared it with voided urinary cytology. UCA1 expression was found in T24 cell line and also found to be significantly higher in the cancer group as compared to the controls (p < 0.001). UCA1 messenger RNA (mRNA) expression showed a significant (p < 0.05) association with stage and grade (p < 0.05). UCA1 showed a sensitivity of 79.49 % and a specificity of 79.73 % (p < 0.001), whereas urine cytology had a sensitivity of 66.67 % and a specificity of 95.95 % for TCC cases. Higher expression of UCA1 was associated with high grade (G2–G3, sensitivity = 84.09 %) (p < 0.001). UCA1 mRNA expression did not significantly correlate with the patient’s age, sex, and smoking habit (p > 0.05). UCA1 can be used as a non-invasive diagnostic biomarker for TCC bladder as an adjunct to cytology in the early diagnosis of primary urinary bladder cancer.


  • Evaluation of urinary XIAP as a diagnostic biomarker of carcinoma of urinary bladder

    by A. K. Srivastava, P. K. Singh, D. Singh, D. Dalela, S. K. Rath, M. M. Goel, M. L. B. Bhatt

    Early diagnosis of carcinoma of the bladder remains a challenge. Urine cytology, as an adjunct to cystoscopy, is less sensitive for low-grade tumors. X-linked inhibitor of apoptosis (XIAP), a negative regulator of apoptotic stimuli and a member of apoptosis family, is frequently activated in bladder carcinoma. Our aim is to investigate the significance of urinary XIAP for the noninvasive diagnosis of transitional cell carcinoma (TCC) of the urinary bladder. We examined urinary XIAP expression in a bladder cancer cell line (T24) and in urine of 28 healthy individuals, 46 patients of nonmalignant disorders, and 117 cases (69 primary and 48 recurrent cases) of histologically proven TCC prior to transurethral resection, by using real-time PCR, and compared it with voided urinary cytology (VUC). XIAP expression was found in T24 cell line and also was found to be significantly higher in the cancer group as compared to the controls (p < 0.001). XIAP messenger RNA (mRNA) expression showed a significant (p < 0.05) association with stage and grade (p < 0.05). XIAP shows the sensitivity of 82.91 % and specificity of 78.38 % (p < 0.001), whereas urine cytology had sensitivity of 66.67 % and specificity of 95.95 % for TCC cases. The combination of XIAP and VUC had better sensitivity (98.2 %) and specificity (92.6 %) than they showed individually (p < 0.001). XIAP mRNA expression did not significantly correlated with the patient’s age, sex, and smoking (p > 0.05). Urinary XIAP can be used as a noninvasive diagnostic biomarker for bladder TCC in adjunct to cytology mainly for low-grade non-muscle-invasive tumors.